CLSD
Price
$0.85
Change
+$0.05 (+6.25%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
65.57M
13 days until earnings call
NXTC
Price
$0.39
Change
-$0.03 (-7.14%)
Updated
Apr 24, 04:56 PM (EDT)
Capitalization
11.73M
7 days until earnings call
Ad is loading...

CLSD vs NXTC

Header iconCLSD vs NXTC Comparison
Open Charts CLSD vs NXTCBanner chart's image
Clearside Biomedical
Price$0.85
Change+$0.05 (+6.25%)
Volume$700
Capitalization65.57M
NextCure
Price$0.39
Change-$0.03 (-7.14%)
Volume$100
Capitalization11.73M
CLSD vs NXTC Comparison Chart
Loading...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLSD vs. NXTC commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLSD is a Hold and NXTC is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CLSD: $0.80 vs. NXTC: $0.42)
Brand notoriety: CLSD and NXTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLSD: 117% vs. NXTC: 139%
Market capitalization -- CLSD: $65.57M vs. NXTC: $11.73M
CLSD [@Biotechnology] is valued at $65.57M. NXTC’s [@Biotechnology] market capitalization is $11.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLSD’s FA Score shows that 0 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • CLSD’s FA Score: 0 green, 5 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, NXTC is a better buy in the long-term than CLSD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLSD’s TA Score shows that 5 TA indicator(s) are bullish while NXTC’s TA Score has 4 bullish TA indicator(s).

  • CLSD’s TA Score: 5 bullish, 5 bearish.
  • NXTC’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NXTC is a better buy in the short-term than CLSD.

Price Growth

CLSD (@Biotechnology) experienced а -8.30% price change this week, while NXTC (@Biotechnology) price change was +25.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

CLSD is expected to report earnings on Aug 18, 2025.

NXTC is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLSD($65.6M) has a higher market cap than NXTC($11.7M). CLSD YTD gains are higher at: -16.042 vs. NXTC (-45.512). CLSD has higher annual earnings (EBITDA): -22.23M vs. NXTC (-54.34M). NXTC has more cash in the bank: 68.6M vs. CLSD (23.6M). CLSD has less debt than NXTC: CLSD (785K) vs NXTC (5.95M). CLSD has higher revenues than NXTC: CLSD (7.7M) vs NXTC (0).
CLSDNXTCCLSD / NXTC
Capitalization65.6M11.7M561%
EBITDA-22.23M-54.34M41%
Gain YTD-16.042-45.51235%
P/E RatioN/AN/A-
Revenue7.7M0-
Total Cash23.6M68.6M34%
Total Debt785K5.95M13%
FUNDAMENTALS RATINGS
CLSD vs NXTC: Fundamental Ratings
CLSD
NXTC
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8596
P/E GROWTH RATING
1..100
71100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (14) in the Biotechnology industry is significantly better than the same rating for CLSD (90) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew significantly faster than CLSD’s over the last 12 months.

NXTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to CLSD’s over the last 12 months.

NXTC's SMR Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to CLSD’s over the last 12 months.

CLSD's Price Growth Rating (85) in the Pharmaceuticals Major industry is in the same range as NXTC (96) in the Biotechnology industry. This means that CLSD’s stock grew similarly to NXTC’s over the last 12 months.

CLSD's P/E Growth Rating (71) in the Pharmaceuticals Major industry is in the same range as NXTC (100) in the Biotechnology industry. This means that CLSD’s stock grew similarly to NXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLSDNXTC
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 15 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 16 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRLB33.810.51
+1.53%
Proto Labs
SKT31.860.17
+0.54%
Tanger
GRNQ0.93N/A
N/A
Greenpro Capital Corp
BCBP8.69-0.16
-1.81%
BCB Bancorp
AVY170.25-4.58
-2.62%
Avery Dennison Corp

CLSD and

Correlation & Price change

A.I.dvisor tells us that CLSD and INBX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLSD and INBX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
-0.30%
INBX - CLSD
28%
Poorly correlated
+2.44%
IKNA - CLSD
27%
Poorly correlated
+1.68%
VCYT - CLSD
27%
Poorly correlated
+1.08%
INAB - CLSD
26%
Poorly correlated
+5.39%
NXTC - CLSD
25%
Poorly correlated
+4.89%
More